Most importantly, combination treatment in SHH-MB was more efficacious in inhibiting tumor cell proliferation than both monotherapies, while combination treatment in Group3-MB did not show any benefit over DNMT1 inhibition alone. This evidence concerns the gene DNMT1 and neoplasm.